NextCure Analyst Price Targets - Benzinga

NextCure Inc

NXTCNASDAQ

Trade with Public

Trade with Public

$5.91

0.213.78%

Últ. Act.: Nov 3, 4:00 PM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Informe de acciones

NextCure Analyst Price Targets - Benzinga

NextCure Analyst Price Targets

Wall Street analyst price targets and consensus rating for NextCure (NXTC).

Price Target Range — 9 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$28Upside to Avg. PT+373.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 11, 2026	LUCID CAPITAL MARKETS	Christopher Liu	Initiate	Buy	$25
Nov 7, 2025	Ladenburg Thalmann	Kevin DeGeeter	Upgrade	Neutral→Buy	$18
Jul 15, 2025	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$36→$15
Jul 1, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$36
Mar 17, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$36
Mar 7, 2025	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$48→$36
Nov 11, 2024	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$96→$48
Aug 2, 2024	Needham	Gil Blum	Maintained	Buy	$48
Jun 3, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$96
May 31, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$96
May 3, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$96
May 3, 2024	Needham	Gil Blum	Maintained	Buy	$48
Mar 22, 2024	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$60→$96
Mar 20, 2024	Needham	Gil Blum	Maintained	Buy	$48
Dec 14, 2023	Needham	Gil Blum	PT Cut	Buy	$72→$48

Analyst Ratings News

PRO
LUCID CAPITAL MARKETS Initiates Coverage On NextCure with Buy Rating, Announces Price Target of $25

LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on NextCure (NASDAQ:NXTC) with a Buy rating and announces Price Target of $25.

Benzinga Newsdesk

PRO
Ladenburg Thalmann Upgrades NextCure to Buy, Announces $18 Price Target

Ladenburg Thalmann analyst Kevin DeGeeter upgrades NextCure (NASDAQ:NXTC) from Neutral to Buy and announces $18 price target.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on NextCure, Lowers Price Target to $15

Piper Sandler analyst Edward Tenthoff maintains NextCure (NASDAQ:NXTC) with a Overweight and lowers the price target from $36 to $15.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on NextCure, Maintains $3 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $3 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on NextCure, Lowers Price Target to $3

HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $4 to $3.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on NextCure, Lowers Price Target to $4

HC Wainwright & Co. analyst Emily Bodnar maintains NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $8 to $4.

Benzinga Newsdesk